Literature DB >> 9582090

Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate.

S Dirnhofer1, C Berger, M Hermann, G Steiner, S Madersbacher, P Berger.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) affects the majority of elderly men, and prostate cancer is the most common male cancer. Prostatic growth and function are thought to be regulated by steroid hormones, primarily androgens and estrogens, but nonandrogenic hormones must also be considered. The increasing evidence of para/autocrine functions of the gonadotropic glycoprotein-hormones (GPH), their allocation to the superfamily of cystine-knot growth factors, and luteinizing hormone (LH)/chorionic gonadotropin (CG)-receptor (R) gene expression in nongonadal tissues led us to investigate intraprostatic GPH and GPH-R gene expression. METHODS AND
RESULTS: RT-PCR and subsequent Southern hybridization and/or restriction enzyme analysis of BPH and prostatic adenocarcinoma demonstrated that all three human (h) gonadotropic hormones, i.e., follicle-stimulating hormone (FSH), LH, and CG, as well as the corresponding FSH-R and LH/CG-R, are transcribed intraprostatically. Significant amounts of the alpha and beta subunits of hCG were secreted by short-term primary cultures of human BPH tissues, as detected by highly sensitive and specific time-resolved immunofluorometric assays (IFMAs).
CONCLUSIONS: Our data suggest that prostatic- and pituitary-derived GPH act directly on the prostatic gland, particularly FSH via the FSH-R, thereby possibly modulating locally acting key hormones and growth factors involved in BPH development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582090     DOI: 10.1002/(sici)1097-0045(19980515)35:3<212::aid-pros7>3.0.co;2-i

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Experimental use of GnRH antagonists as second-line hormonal therapy.

Authors:  Tomasz M Beer
Journal:  Rev Urol       Date:  2004

2.  Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27).

Authors:  Kurt Miller; Gabriele Simson; Sandra Goble; Bo-Eric Persson
Journal:  Ther Adv Urol       Date:  2015-06

Review 3.  The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.

Authors:  Benjamin A Gartrell; Che-kai Tsao; Matthew D Galsky
Journal:  Urol Oncol       Date:  2012-04-17       Impact factor: 3.498

4.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02

5.  Fine-scale quantification of HCG beta gene transcription in human trophoblastic and non-malignant non-trophoblastic tissues.

Authors:  K Rull; P Hallast; L Uusküla; J Jackson; M Punab; A Salumets; R K Campbell; M Laan
Journal:  Mol Hum Reprod       Date:  2007-11-29       Impact factor: 4.025

6.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

7.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

8.  Decreased levels of genuine large free hCG alpha in men presenting with abnormal semen analysis.

Authors:  Christoph Zenzmaier; Regine Gerth; Matthias Gruschwitz; Herbert Lindner; Eugen Plas; Peter Berger
Journal:  Reprod Biol Endocrinol       Date:  2011-08-12       Impact factor: 5.211

9.  Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH).

Authors:  S Davies; C M Bax; E Chatzaki; T Chard; R K Iles
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

10.  Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer.

Authors:  Hisamitsu Ide; Yuichi Terado; Kentaro Sakamaki; Masahiro Inoue; Akiko Nakajima; Yan Lu; Schinichi Hisasue; Raizo Yamaguchi; Satoru Muto; Shigeo Horie
Journal:  Prostate Int       Date:  2013-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.